A Phase III Trial Evaluating Fruquintinib Efficacy and Safety in 3+ Line Colorectal Cancer Patients （FRESCO)
Status:
Completed
Trial end date:
2017-01-17
Target enrollment:
Participant gender:
Summary
Fruquintinib administered at 5mg once daily(QD) in 4 weeks treatment cycle (three weeks on
and one week off) was well tolerated and demonstrated encouraging preliminary clinical
antitumor activity in patients with metastatic colorectal cancer (CRC) in phase Ib and phase
2 study. This study is aimed to evaluate the efficacy and safety of Fruquintinib in the
treatment of patients with metastatic CRC who have progressed after second line or above
standard chemotherapy
Phase:
Phase 3
Details
Lead Sponsor:
Hutchison Medipharma Limited
Collaborators:
Eighty-One Hospital of People's Liberation Army Fudan University